AIMS Programs:  Next generation immune therapies endeavoring to deliver immune homeostasis

CYTO-200 AIMS™ Program

noroxymorphone-n-substituted-methyl cyclopropyl

Discovery Lead Optimization Pre-Clinical Phase 1 Phase 2 Phase 3 NDA
Crohn's Disease
COVID-19
Fibromyalgia
MS

CYTO-400 AIMS™ Program

Proenkephalin

Discovery Lead Optimization Pre-Clinical Phase 1 Phase 2 Phase 3 NDA
Pancreatic Cancer
Hepatocellular

CYTO-600 Program

TLR5 Platform

Discovery Lead Optimization Pre-Clinical Pivotal Animal Studies Human Safety / Dose Conversion
Acute Radiation Sickness
Discovery Lead Optimization Pre-Clinical Phase 1 Phase 2 Phase 3 NDA
Oncology
Vaccine Adjuvants